Asuragen Launches Cancer Panels Optimized for FFPE Tissue; Plans to Sell Proprietary Reagents | GenomeWeb

Asuragen has launched two next-gen sequencing cancer panels and plans to roll them out as services in its CLIA-certified laboratory by the beginning of June. The panels, SuraSeq-200 and SuraSeq-500, assess 200 and 500 hotspot mutations across five and 17 oncogenes, respectively.

The panels were designed in-house using proprietary reagents and methods and have been optimized to assess samples from low-quality formalin-fixed, paraffin-embedded tissue. Asuragen eventually plans to market the reagents themselves as products.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.